Fluorescent polyQ-YFP aggregation reporter as a neurodegeneration screening model
Polyglutamine (polyQ) expansion diseases — Huntington's disease, several spinocerebellar ataxias — are caused by CAG-repeat expansions that produce toxic, aggregation-prone proteins. C. elegans strains expressing expanded polyQ tracts fused to a fluorescent protein recapitulate the core cell biology of aggregation in a living, transparent animal that can be screened at scale.
Glutamine-rich (polyQ) tracts below roughly 35-40 repeats fold as an extended, soluble, largely disordered segment that does not impair the fused protein's solubility. Above this threshold, the tract nucleates into beta-sheet-rich amyloid-like aggregates through a polymerization mechanism analogous to prion nucleation: a slow, rate-limiting nucleation step followed by rapid templated growth once a seed forms.
Standard C. elegans reporter lines bracket this threshold — a Q0 or Q19 control remains diffuse for the animal's entire life, while Q35, Q40, or Q82 lines develop progressively earlier and more numerous aggregates, allowing researchers to dial in assay sensitivity and dynamic range for a given screening purpose.
Because polyQ aggregation is length- and concentration-dependent but not sequence-specific beyond the repeat itself, the same nucleation biophysics is thought to apply broadly to other aggregation-prone disease proteins (tau, alpha-synuclein, TDP-43), making polyQ reporters a general proteostasis-capacity readout, not just a Huntington's model.
The unc-54 myosin promoter drives strong, specific expression in body-wall muscle cells — large, easily imaged cells arranged in four longitudinal quadrants beneath the cuticle. Muscle-restricted expression offers practical screening advantages: aggregates are large, bright, and easily counted by eye or automated image analysis without needing to resolve individual neurons.
Other available promoters extend the same aggregation biology to different tissues: pan-neuronal promoters (rgef-1, unc-119) model neurodegeneration more directly, while intestinal promoters (ges-1) probe non-neuronal proteostasis and connect to organismal metabolic health. The choice of tissue determines both the phenotype read out (motility for muscle, chemotaxis/associative learning for neurons) and how directly the model maps onto neurodegenerative disease.
The core polyQ-YFP line is typically crossed or co-expressed with additional tools: RFP-tagged organelle markers (mitochondria, ER) to test for aggregate co-localization or organelle stress, temperature-sensitive sterile mutations (glp-1) to eliminate germline proliferation without chemical sterilants, and RNAi-hypersensitive backgrounds to enable robust feeding-RNAi modifier screens on the same reporter animal.
Immediately after the final larval molt, polyQ-YFP reporter animals display smooth, cytoplasmically diffuse fluorescence throughout body-wall muscle. This baseline window is the reference state used to normalize all subsequent aggregation scoring.
Animals are immobilized for imaging using sodium azide or levamisole anesthetic on agarose pads, or increasingly via microfluidic worm-trapping chips that allow repeated non-destructive imaging of the same individual across its lifespan — a major advantage for longitudinal aggregation studies, since it removes inter-animal variability from the comparison.
At baseline, fluorescence intensity is quantified per animal to confirm uniform transgene expression, and animals with visibly abnormal (mosaic or silenced) expression from extrachromosomal array loss are excluded, since C. elegans transgenic arrays are mitotically unstable and can be stochastically lost in a fraction of cells or animals.
Compound screens are typically initiated at this early larval/young-adult stage, before aggregation begins, so that the test compound is present throughout the nucleation-and-growth window rather than added after aggregates have already formed. This "preventive" dosing paradigm tests a compound's ability to block aggregate formation, which is mechanistically distinct from testing whether a compound can dissolve pre-formed aggregates (a much harder pharmacological problem relevant to reversing established disease).
Extrachromosomal transgenic arrays are lost stochastically during cell division, producing "mosaic" expression. Many labs prefer integrated single-copy insertion (MosSCI) reporter lines for quantitative aggregation assays because they give uniform, single-copy expression across all animals and cells.
As animals age past the first days of adulthood, polyQ-YFP nucleates into discrete, bright, immobile puncta — the visual signature of amyloid-like protein aggregation. Foci number is the primary quantitative phenotype scored in virtually all polyQ screening pipelines.
PolyQ aggregation follows classic nucleated polymerization kinetics: a slow, stochastic nucleation phase in which a small number of misfolded monomers form an initial seed, followed by rapid, thermodynamically favorable templated growth as additional monomers add onto the existing aggregate. This produces the characteristic age-dependent, roughly sigmoidal accumulation curve of foci number seen in live imaging.
Because nucleation is stochastic and concentration-dependent, small differences in expression level, temperature, or genetic background produce visible differences in aggregation onset timing — a key reason why highly uniform integrated reporter lines and tightly controlled rearing temperature (typically 20°C) are essential for reproducible quantitative screening.
Manual foci counting under a fluorescence dissecting scope remains common in small studies but does not scale to compound libraries. Automated image analysis pipelines segment each worm from a well or plate image, apply local-maxima or blob-detection algorithms tuned to typical foci size (~1-3 µm), and output a per-worm foci count alongside total fluorescence intensity (a proxy for total reporter expression, used to normalize foci counts and exclude non-expressing animals).
High-content imaging systems can process a 96- or 384-well plate of worms in minutes, enabling foci counting across thousands of animals per compound-screening run — a scale that would be impractical by eye.
Foci counts alone can be confounded by expression-level differences between animals. Robust pipelines normalize foci number to total YFP intensity per worm, and require aggregates to be immobile across sequential frames to exclude bright motile artifacts (e.g., gut autofluorescent granules) from being miscounted as polyQ foci.
Accumulating protein aggregates place chronic stress on the cellular protein quality-control machinery. C. elegans mounts a coordinated, transcriptionally regulated proteostasis response — but with age, this response weakens, and aggregation accelerates in a feed-forward decline that mirrors what is thought to occur in aging human neurons.
Heat-shock factor 1 (HSF-1) is the master transcriptional regulator of the cytosolic protein quality-control response, normally held inactive in a complex with HSP-70/HSP-90 chaperones. Accumulating misfolded protein — including polyQ aggregates — titrates chaperones away from HSF-1, freeing it to trimerize, bind heat-shock elements in target gene promoters, and induce a battery of chaperones including small heat-shock proteins (HSP-16 family), HSP-70, and HSP-40 co-chaperones.
A widely used co-reporter, phsp-16.2::GFP, directly visualizes this response: GFP expression spikes in cells experiencing proteotoxic stress, providing a live readout of chaperone induction that can be imaged alongside polyQ aggregation in the same animal.
HSF-1 activity and chaperone-network capacity decline progressively with adult age in C. elegans, a phenomenon linked mechanistically to reduced insulin/IGF-1 signaling output and correlated with the animal's overall rate of aging. This creates the feed-forward pathology characteristic of proteinopathies: early aggregates are efficiently buffered by a robust chaperone response, but as chaperone capacity declines with age, each new misfolding event is less effectively contained, causing aggregation to accelerate non-linearly in later adulthood — a dynamic proposed to parallel the age-dependence of human neurodegenerative disease onset, which occurs overwhelmingly in older individuals despite disease-causing mutations being present from birth.
Genetic manipulations that boost proteostasis capacity — daf-2 (insulin receptor) loss-of-function, or HSF-1 overexpression — robustly delay polyQ aggregation and extend "healthspan" in these models, directly linking the aging and proteostasis-collapse pathways and motivating compound screens for molecules that pharmacologically mimic this effect.
The quantitative, age-dependent foci phenotype makes polyQ reporter worms an efficient primary screening platform for candidate neurodegenerative disease therapeutics — compounds are ranked by their ability to reduce aggregate burden, preserve motility, or both, relative to vehicle-treated controls.
Compounds are typically dissolved into NGM agar or liquid culture medium starting from the L1 or L4 stage, so exposure spans the aggregation-onset window. At a fixed endpoint (commonly day 5-8 of adulthood), animals are imaged and scored for foci number relative to vehicle-only controls on the same plate.
Secondary assays test whether reduced aggregation translates to preserved function: body-bend thrashing rate in liquid, crawling speed on agar, or — for neuronal-expressing polyQ lines — chemotaxis and associative learning assays. A compound that reduces visible foci but fails to improve any functional readout is a weaker candidate than one that improves both, since the ultimate goal is functional preservation, not merely fewer visible puncta.
Compounds emerging from polyQ worm screens have historically clustered into a small number of mechanistic classes: chaperone/heat-shock response inducers (which boost the cell's intrinsic refolding capacity), autophagy and proteasome activators (which boost aggregate clearance rather than prevention), and direct small-molecule aggregation inhibitors that bind the polyQ tract or early oligomeric species and block nucleation.
Spermidine and related autophagy-inducing polyamines, and mTOR-pathway inhibitors such as rapamycin, have shown activity in these worm aggregation models, echoing their independent identification as longevity-extending compounds — reinforcing the mechanistic overlap between the aging and proteostasis pathways.
A critical translational filter is counter-screening in Q0/Q19 non-aggregating control worms: a compound that "reduces foci" by simply suppressing transgene expression or being generally toxic (reducing overall protein synthesis) is a false positive and must be distinguished from a genuine proteostasis-enhancing hit.
| Product | Indication | Trial Design | Key Result |
|---|---|---|---|
| HSP/chaperone inducers | HSF-1 pathway | Boost chaperone expression to refold or buffer misfolded polyQ | Broadly protective across proteinopathy models |
| Autophagy activators | mTOR / ULK1 axis | Enhance autophagic clearance of aggregates and damaged organelles | Overlaps with longevity-pathway pharmacology (e.g. rapamycin) |
| Direct aggregation inhibitors | polyQ oligomers | Bind nascent oligomers, block nucleation/templated growth | Mechanistically specific, low off-target risk |
| Proteasome enhancers | Ubiquitin-proteasome system | Increase degradation flux for misfolded monomers before aggregation | Targets earliest stage of the aggregation cascade |